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Abstract
Phospholipase D (PLD) is distributed widely in mammalian tissues where it is believed to play an important role in the
regulation of cell functions and cell fate by a variety of extracellular signals. In this study, we used primary cultures of rabbit
connecting tubule (CNT) and cortical collecting duct (CCD) cells, grown to confluence on a permeable support, to
investigate the possible involvement of PLD in the mechanism of action of hormones that regulate Ca2 reabsorption. RT-
PCR revealed the presence of transcripts of PLD1b and PLD2, but not PLD1a, in these cultures. Moreover, the expression of
substantial amounts of PLD1 protein was demonstrated by Western blotting. To measure PLD activity, cells were labelled
with [3H]myristic acid after which the PLD-catalysed formation of radiolabelled phosphatidylethanol ([3H]PtdEth) was
measured in the presence of 1% (v/v) ethanol. Deamino-Cys,D-Arg8-vasopressin (dDAVP) and N6-cyclopentyladenosine
(CPA), two potent stimulators of Ca2 transport across these monolayers, stimulated PLD activity as was indicated by a
marked increase in [3H]PtdEth. Similarly, ATP, a potent inhibitor of dDAVP- and CPA-stimulated Ca2 transport,
increased the formation of [3H]PtdEth. PLD activity was furthermore increased by 8Br-cAMP and following acute (30 min)
stimulation of protein kinase C (PKC) with a phorbol ester (PMA). Chronic PMA treatment (120 h) to downregulate
phorbol ester-sensitive PKC isoforms did not affect PLD activation by dDAVP, CPA and 8Br-cAMP, while markedly
decreasing the effect of ATP and abolishing the effect of PMA. The PKC inhibitor chelerythrine significantly reduced PLD
activation by dDAVP, CPA and 8Br-cAMP, without changing the effect of ATP. The inhibitor only partially reduced the
effect of PMA. This study shows that Ca2 transporting cells of CNT and CCD contain a regulated PLD activity. The
physiological relevance of this activity, which is not involved in Ca2 reabsorption, remains to be established. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
In mammals, the distal part of the nephron is the
major regulatory site for Ca2 excretion in the urine
[1,2]. Hormone-regulated active Ca2 reabsorption
proceeds against a transepithelial electrochemical
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gradient and involves several components, each of
which forms a potential target of hormone action.
In the ¢rst place, a Ca2 in£ux pathway, probably
the recently cloned epithelial Ca2 channel (ECaC)
[3], present in the luminal membrane of the cell al-
lows Ca2 to passively £ow into the cytosolic com-
partment down a steep electrochemical gradient.
Next, a vitamin D-dependent Ca2 binding protein
(calbindin-D28K) binds Ca2 with high a⁄nity and
shuttles it to the basolateral membrane. Finally, a
plasma membrane Ca2-ATPase and Na^Ca2 ex-
changer transport Ca2 out of the cytosol against a
steep electrochemical gradient. Presently, it is un-
known which component of the Ca2 reabsorptive
mechanism is subject to hormone-activated second
messenger systems.
Previous work has shown that Ca2 reabsorption
in primary cultures of cells from rabbit connecting
tubule (CNT) and cortical collecting duct (CCD) is
stimulated by various hormones, including parathy-
roid hormone (PTH) [4,5], vasopressin [4^6], adeno-
sine [4,7], prostaglandin E2 [4,5] and atrial natriuretic
peptide [8], and that ATP, which in itself does not
a¡ect basal Ca2 reabsorption, signi¢cantly inhibits
the e¡ect of the stimulatory hormones [9,10]. It was
demonstrated that the action of the stimulatory hor-
mones was independent of cAMP, insensitive to
chronic phorbol ester treatment and markedly inhib-
ited by the protein kinase C (PKC) inhibitor cheler-
ythrine, suggesting the involvement of a phorbol es-
ter-insensitive, chelerythrine-inhibitable PKC isoform
[4]. By contrast, chronic phorbol ester treatment was
shown to abolish the inhibitory e¡ects of both the
phorbol ester and ATP on hormone-stimulated Ca2
reabsorption [8,10,11]. These ¢ndings were taken as
evidence that ATP acts primarily via a downregulat-
able PKC isoform to inhibit hormone-stimulated
Ca2 reabsorption at the level of the pathway involv-
ing the non-downregulatable PKC isoform [9]. The
possibility of a non-cAMP-mediated mechanism in-
volved in hormone-stimulated Ca2 reabsorption was
¢rst considered by Poujeol and coworkers studying
calcitonin-induced Ca2 mobilisation in rabbit con-
voluted distal tubule cultures [12]. A major role of
PKC in PTH-stimulated Ca2 reabsorption was also
deduced from studies with immortalised mouse distal
convoluted tubule cells and primary cultures of
mixed mouse CNT and cortical thick ascending
limb cells [13].
The ¢nding that di¡erential activation of phorbol
ester-sensitive and -insensitive PKC isoforms is the
underlying principle in the action of inhibitory and
stimulatory hormones on Ca2 reabsorption raises
the question of the mechanism of activation of these
isoforms. The physiological activator of PKC is di-
acylglycerol and the hormone-induced formation of
this lipid involves the action of hormone-sensitive
phospholipases such as phosphatidylinositol-speci¢c
phospholipase C (PtdIns-PLC) and phosphatidylcho-
line-speci¢c phospholipase D (PtdCho-PLD) [14,15].
The latter phospholipase hydrolyses PtdCho to yield
phosphatidic acid and it has been proposed that
phosphatidic acid is rapidly converted to diacyl-
glycerol to activate PKC [16]. Since the diacyl-
glycerols derived from PtdIns and PtdCho di¡er in
fatty acid composition it is very well possible that
they may activate di¡erent PKC isoforms [17]. In a
recent study, evidence was provided that PTH acts
through a pathway other than that involving PtdIns-
PLC to promote the formation of PKC activating
diacylglycerols [18]. PTH was shown to activate
PtdCho-PLD and it was suggested that PTH acts
through this pathway to increase diacylglycerol. Hor-
mone-induced increases in PLD activity were also
reported in rabbit CCD cells [19]. In this latter study,
bradykinin-induced PLD activation was shown to be
paralleled by inhibition of sphingomyelinase activity
thus excluding the possibility that bradykinin acts
through ceramide to activate PLD.
It has been demonstrated that agonists which stim-
ulate the hydrolysis of PtdCho also cause the forma-
tion of phosphatidyl alcohols as a result of the PLD-
catalysed transphosphatidylation reaction [20]. The
present study uses this PLD-speci¢c transphospha-
tidylation reaction to test the possibility that PLD
is selectively activated by either the inhibitory or
the stimulatory hormones of Ca2 transport.
2. Materials and methods
2.1. Materials
Collagenase A and hyaluronidase were obtained
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from Boehringer (Mannheim, Germany) and deami-
no-Cys,D-Arg8-vasopressin (dDAVP) from Bachem
Feinchemikalien (Bubendorf, Switzerland). N6-Cy-
clopentyladenosine (CPA), ATP, 8Br-cAMP, indo-
methacin, 12-O-tetradecanoyl phorbol 13-acetate
(PMA) and 2,2,4-trimethylpentane were purchased
from Sigma (St. Louis, MO, USA). Chelerythrine
and pertussis toxin were obtained from Research
Biochemicals International (Cologne, Germany) and
[9,10(n)-3H]myristic acid (53 Ci/mmol) from The
Radiochemical Centre (Amersham, UK). HPTLC
silica-gel 60 plates, ethyl acetate and chloroform
were purchased from Merck (Darmstadt, Germany),
phospholipid standards from Avanti Polar Lipids
(Birmingham, AL, USA), and 2P,5P-dideoxyaden-
osine (DDA) from Biomol (Plymouth Meeting,
PA, USA). All other chemicals were of reagent
grade.
2.2. Primary cultures of rabbit kidney cortical
collecting system
Rabbit kidney CNT and CCD cells were immuno-
dissected from kidney cortex of young New Zealand
White rabbits (V0.5 kg) with antibody R2G9 and
set in primary culture on permeable supports (0.33
cm2 ; Costar, Cambridge, MA, USA) as described in
detail previously [21]. The culture medium was a 1:1
mixture of Dulbecco’s modi¢ed Eagle’s medium and
Ham’s F-12 medium (DME/F12; Gibco, Paisley,
UK) supplemented with 5% (v/v) decomplemented
foetal calf serum, 50 Wg/ml gentamicin, 10 Wl/ml
non-essential amino acids (Gibco), 5 Wg/ml insulin,
5 Wg/ml transferrin, 50 nM hydrocortisone, 70 ng/ml
prostaglandin E1, 50 nM Na2SeO3, and 5 pM triio-
dothyronine, equilibrated with 5% CO2^95% air at
37‡C. PLD measurements were performed 8 days
after seeding the cells.
2.3. RNA extraction and reverse transcription
(RT)-PCR
Total RNA was isolated from rat brain and pri-
mary cultures of CNT and CCD cells using Trizol
(Gibco, Paisley, UK) and reverse-transcribed with
M-MLV reverse transcriptase using random hexam-
er-mixed oligonucleotides. Speci¢c primers for the
ampli¢cation of PLD1 transcripts were designed on
the basis of published sequences from rat liver [22].
Primers were chosen such that they made it possible
to discriminate between PLD1a and PLD1b. The
sense and antisense primers were 5P-GCCTATGGA-
AGGTGGGACGAC-3P and 5P-GGAGTACCTGT-
CAATGAAATCAGC-3P, respectively. Primers to
speci¢cally amplify PLD2 transcripts were designed
on the basis of the published sequence of rat brain
PLD2 [23]. In this case, the sense and antisense prim-
ers were 5P-GAACAGGGGCAGTGTTTCCGA-3P
and 5P-CGCTGTTTCTTGCCACAGCTG-3P, re-
spectively. The PCR of PLD1 and PLD2 transcripts
was based on 35 cycles of 1 min at 94‡C, 1 min at
55‡C and 1 min at 72‡C, with an elongation time of
10 min at 72‡C following the last cycle. DNA prod-
ucts, visualised by means of ethidium bromide stain-
ing, were scanned with an Imaging Densitometer
(Bio-Rad, Munich, Germany).
2.4. Western blotting
Total cell lysates (100 Wg) from primary cultures of
rabbit CNT and CCD cells were subjected to SDS^
PAGE. Proteins were transferred overnight to poly-
vinylidine di£uoride membranes (Immobilon P,
Millipore, Bedford, MA, USA). Membranes were
blocked for 1 h at room temperature with phos-
phate-bu¡ered saline (PBS) (pH 7.4) containing 1%
(w/v) milk powder and 0.1% (v/v) Tween-20 (PBST-
MLK). Subsequently, the blots were incubated over-
night at 4‡C with the rabbit anti-hPLD1 antibody
described by Mu«ller-Wieprecht et al. [24] diluted
1:1000 in PBST-MLK. The antibody was kindly pro-
vided by Prof. Dr. C.C. Geilen (University Medical
Center Benjamin Franklin, The Free University of
Berlin, Germany). Immunoreactive protein was de-
tected by incubating the blots for 1 h at room tem-
perature with goat anti-rabbit IgG antibody conju-
gated to alkaline phosphatase diluted 1:1000 in
PBST-MLK. Membranes were washed with PBS
(pH 7.4) containing 0.1% (v/v) Tween-20 and stained
with 0.1 M diethanolamine, 0.34 mg/ml nitroblue
tetrazolium, 0.18 mg/ml 5-bromo-4-chloro-3-indolyl-
phosphate and 1.0 M MgCl2. The membranes were
scanned with an Imaging Densitometer (Bio-Rad,
Munich, Germany).
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2.5. PLD measurements
PLD measurements were performed essentially as
described previously [25,26]. Brie£y, monolayers, la-
belled with [3H]myristic acid (3 WCi/ml) for 24 h,
were washed and incubated in DME/F12 containing
5 WM indomethacin for another 3 h. Subsequently,
the monolayers were washed and preincubated in a
physiological salt solution (PSS) containing 140 mM
NaCl, 2 mM KCl, 1 mM K2HPO4, 1 mM KH2PO4,
1 mM MgCl2, 1 mM CaCl2, 5 mM glucose, 5 mM L-
alanine, 5 WM indomethacin and 10 mM HEPES
(adjusted to pH 7.40 with Tris) for 15 min. Next,
the monolayers were washed and incubated in PSS
containing 1% (v/v) ethanol and the agonist(s) of
interest for another 30 min. At 30 min, the ¢lter
was excised and rapidly transferred into a lipid
tube (Sarstedt, Essen, Germany) containing 1 ml of
methanol, 500 Wl of chloroform and 400 Wl of water
(4‡C). The extract was mixed vigorously and phase
separation was achieved by addition of 400 Wl of
chloroform and 400 Wl of water followed by centri-
fugation. The lower organic phase was collected and
blown to dryness with N2. The dried extracts were
dissolved in 20 Wl of chloroform/methanol (9:1, v/v)
and the lipids were separated by TLC using potassi-
um oxalate-treated silica-gel 60 HPTLC plates. The
plates were developed with the upper phase of a
mixture of ethyl acetate/2,2,4-trimethylpentane/acetic
acid/water (13:2:3:10, v/v). Radioactive spots corre-
sponding to authentic lipid standards were visualised
by I2 staining and scraped o¡. Radioactivity was
measured by liquid scintillation spectrometry.
2.6. Analysis of the data
The data presented are expressed as the mean
þ S.E.M. of the number of experiments indicated.
Overall statistical signi¢cance was determined by
analysis of variance. In the case of signi¢cance
(P6 0.05), individual groups were compared accord-
ing to Fisher. P values of less than 0.05 were consid-
ered signi¢cant.
3. Results
To investigate the PLD isoform composition of
primary cultures of rabbit CNT and CCD cells we
performed RT-PCR using speci¢c primers for PLD1,
which allowed us to discriminate between the two
splice variants of PLD1, PLD1a and PLD1b, and
PLD2. Fig. 1A shows the three PLD transcripts in
total RNA from rat brain for comparison. Cultured
rabbit CNT and CCD cells clearly expressed PLD1b
and PLD2. In contrast, the cells did not express tran-
scripts of PLD1a. Western blot analysis of total cell
lysate was performed to examine the expression of
PLD1b at the protein level. Using an antibody di-
rected against the C- and N-terminal sequences of
human PLD1 we observed a positive band of ex-
pected size of V110 kDa (Fig. 1B). These data
show that primary cultures of rabbit CNT and
Fig. 1. Identi¢cation of PLD transcripts and PLD1 protein in
primary cultures of rabbit CNT and CCD cells. (A) Speci¢c
primers for PLD1, which allowed us to discriminate between
the PLD1 slice variants, PLD1a and PLD1b, and PLD2 were
used to amplify cDNA fragments. In rat brain, the PLD1-spe-
ci¢c primers yielded a larger product of 550 bp and a smaller
product of 450 bp, representing PLD1a and PLD1b, respec-
tively (upper panel; left lane), and one product with the PLD2-
speci¢c primers (lower panel ; left lane). Primary cultures of
rabbit CNT and CCD cells expressed the PLD1b and PLD2
fragments (right lanes). (B) Total cell lysates from primary cul-
tures of rabbit CNT and CCD cells were subjected to SDS^
PAGE and subsequently transferred to polyvinylidine di£uoride
membranes by Western blotting. The membranes were probed
with a speci¢c anti-human PLD1 antibody. The ¢gure shows an
immunoreactive band with an apparent mass of 110 kDa.
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CCD express signi¢cant amounts of PLD1b at both
the mRNA and the protein level.
In order to assess the e¡ects of various hormones
and second messenger systems involved in the regu-
lation of Ca2 reabsorption on PLD activity,
[3H]myristic acid-labelled monolayers of rabbit
CNT and CCD cells were stimulated in the presence
of 1% (v/v) ethanol for 30 min after which the
amount of radiolabelled phosphatidylethanol
([3H]PtdEth) was determined. Incubations were per-
formed in the presence of indomethacin (5 WM)
added 3 h prior to stimulation to inhibit the produc-
tion and release of autostimulatory prostanoids [5].
Under these conditions, basal [3H]PtdEth formation
amounted to 0.44 þ 0.03% (n = 10) of total
[3H]myristic acid-labelled lipid. To study the role of
PKC in hormone-induced PLD activation, mono-
layers were pretreated with PMA (0.1 WM) for 120
h. This treatment is widely used to selectively down-
regulate phorbol ester-sensitive PKC isoforms.
Chronic PMA treatment slightly increased basal
[3H]PtdEth formation to 0.58 þ 0.02% (n = 9) of total
labelled lipid. The data presented hereafter are cor-
rected for basal [3H]PtdEth formation.
Both the phorbol ester PMA (0.1 WM; both sides;
30 min) and the membrane-permeable cAMP ana-
logue 8Br-cAMP (0.1 mM; both sides; 30 min)
markedly increased the formation of [3H]PtdEth
(Fig. 2). The amount of [3H]PtdEth formed during
this acute treatment with PMA was 2.9-fold higher
than that obtained with 8Br-cAMP. Since both drugs
were added at high concentrations, this indicates that
the PKC pathway is much more e¡ective than the
protein kinase A (PKA) pathway in increasing PLD
activity. The combination of PMA and 8Br-cAMP
did not further increase the amount of [3H]PtdEth,
suggesting the absence of a synergistic interaction
between the two pathways. Chronic PMA treatment
(120 h) virtually abolished the stimulatory e¡ect of
acute PMA treatment, while leaving that of 8Br-
cAMP intact.
ATP (0.1 mM; both sides) stimulated the forma-
tion of [3H]PtdEth to the same extent as 8Br-cAMP
(Fig. 3A). The increase obtained with the combina-
tion of ATP and 8Br-cAMP was approximately 1.8-
fold higher than that obtained with each of the two
stimuli alone. The stimulatory e¡ect of ATP was
more than halved following chronic PMA treatment
and in the combination experiment only the stimula-
tion by 8Br-cAMP was left.
The V2 receptor agonist dDAVP (10 nM; basolat-
eral side) evoked a similar increase in the amount of
[3H]PtdEth as ATP and 8Br-cAMP (Fig. 3B). In
combination with ATP, the amount of [3H]PtdEth
was further increased by a factor 2 as compared to
the e¡ect of each stimulus alone. Chronic PMA
treatment did not a¡ect the stimulatory action of
dDAVP, while in the combination it decreased the
amount of [3H]PtdEth practically to the value ob-
Fig. 2. Chronic phorbol ester treatment does not a¡ect 8Br-
cAMP activation of PLD but abolishes the increase in PLD ac-
tivity following acute phorbol ester activation of PKC.
[3H]Myristic acid-labelled primary cultures of rabbit CNT and
CCD cells were incubated with the indicated stimulants in the
presence of 1% (v/v) ethanol for 30 min. Additions were: the
phorbol ester PMA (0.1 WM; both sides), and the membrane-
permeable cAMP analogue 8Br-cAMP (0.1 mM; both sides).
To downregulate phorbol ester-sensitive PKC isoforms, mono-
layers were incubated in the presence of PMA (0.1 WM; both
sides) for 120 h (closed bars). For each ¢lter, the amount of
[3H]PtdEth is expressed as the percentage of total labelled lipid
that was extracted. The data presented for PMA and 8Br-
cAMP alone show the mean þ S.E.M. of at least three ¢lters.
The data presented for the combination of PMA and 8Br-
cAMP are representative of two experiments. pSigni¢cantly
lower than the value obtained with PMA (P6 0.05). *Signi¢-
cantly lower than the value without chronic phorbol ester treat-
ment (P6 0.05).
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Fig. 3. Chronic phorbol ester treatment does not a¡ect 8Br-cAMP, dDAVP or CPA activation of PLD but markedly reduces the ef-
fect of ATP. Chronic phorbol ester treatment (closed bars) and PLD activity measurements were performed as described in the legend
of Fig. 2. Additions were: (A) ATP (0.1 mM; both sides) and/or 8Br-cAMP (0.1 mM; both sides), (B) ATP (0.1 mM; both sides)
and/or dDAVP (10 nM; basolateral side), and (C) ATP (0.1 mM; both sides) and/or CPA (10 WM; apical side). Of note, the values
for 8Br-cAMP are also shown in Fig. 2. For each ¢lter, the amount of [3H]PtdEth is expressed as the percentage of total labelled lipid
that was extracted. The data presented show the mean þ S.E.M. of at least three ¢lters. $Signi¢cantly higher than the value obtained
with either stimulant alone (P6 0.05). *Signi¢cantly lower than the value without chronic phorbol ester treatment (P6 0.05).
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tained with dDAVP alone. Previous work showed
that dDAVP evokes a marked increase in cAMP
that is virtually abolished by the potent adenylyl
cyclase inhibitor 2P,5P-dideoxyadenosine (DDA) [4].
To test whether this increase in cAMP is responsible
for dDAVP-induced PLD activation, monolayers
were stimulated with dDAVP in the presence of
DDA (100 WM, both sides) added 15 min prior to
stimulation. DDA did not signi¢cantly a¡ect
the dDAVP-induced increase in [3H]PtdEth
(0.74 þ 0.11%, n = 3 and 0.72 þ 0.03%, n = 4 in control
and DDA-treated monolayers, respectively).
The adenosine A1 receptor agonist CPA (10 WM;
apical side) increased the amount of [3H]PtdEth to
the same extent as 8Br-cAMP, ATP or dDAVP (Fig.
3C). When added in combination with ATP a 1.8-
fold increase in [3H]PtdEth formation was observed
as compared to the value obtained with ATP alone.
Chronic PMA treatment did not a¡ect the stimula-
tory action of CPA and reduced the e¡ect of the
combination to the value obtained with CPA alone.
CPA-induced PLD activation was not a¡ected in
monolayers pretreated with pertussis toxin (170 ng/
ml) for 24 h, indicating that CPA does not act via Gi
(data not shown).
Table 1 shows that the e¡ects of dDAVP and 8Br-
cAMP were not additive, whereas a 1.5-fold increase
in [3H]PtdEth formation was observed with the com-
bination of CPA and 8Br-cAMP as compared to the
e¡ect of 8Br-cAMP alone. Finally, no additive e¡ect
was observed with the combination of CPA and
dDAVP. In none of these cases did the values ob-
tained with vehicle-treated monolayers di¡er from
those obtained following chronic PMA treatment.
To investigate the role of PKC in more detail
monolayers were stimulated in the presence of the
selective PKC inhibitor chelerythrine (10 WM, both
sides) added 15 min prior to stimulation. In the pres-
ence of chelerythrine, basal [3H]PtdEth formation
amounted to 0.40 þ 0.06% (n = 5) of total
[3H]myristic acid-labelled lipid. PMA-induced
[3H]PtdEth formation was reduced by 60% in mono-
layers treated with chelerythrine (Fig. 4A). Similarly,
this inhibitor virtually abolished the stimulatory ac-
tion of 8Br-cAMP. ATP-induced [3H]PtdEth forma-
tion was not a¡ected by chelerythrine, while the stim-
ulatory actions of dDAVP and CPA were decreased
by 90% and 60%, respectively (Fig. 4B).
4. Discussion
This study demonstrates that Ca2-transporting
cells of rabbit CNT and CCD contain a regulated
PLD activity which is, however, not involved in regu-
lated Ca2 reabsorption. This conclusion is based on
the ¢nding that both stimulatory and inhibitory hor-
mones for Ca2 transport promote the transphos-
phatidylation reaction in primary cultures of rabbit
CNT and CCD cells. This observation also disfa-
vours the idea that selective activation of PtdCho-
speci¢c PLD by either stimulatory or inhibitory hor-
mones underlies their di¡erential activation of phor-
bol ester-insensitive and -sensitive PKC isoforms.
Thus far, two mammalian isoforms of PLD, PLD1
and PLD2, have been cloned from a wide variety of
species [27]. In addition, two alternatively spliced
forms of PLD1 (PLD1a and PLD1b), and three al-
ternatively spliced forms of PLD2 (PLD2a, PLD2b
and PLD2c) have recently been identi¢ed [28,29]. At
present, information on the expression levels, cellular
localisation and function of PLD1 and PLD2 pro-
teins is limited. Using an antibody raised against N-
and C-terminal sequences of human PLD1 [24] we
now show that rabbit cortical collecting system cells
Table 1
Stimulatory hormones for Ca2 reabsorption and 8Br-cAMP
do not increase PLD activity in an additive manner
Stimulant [3H]PtdEth (% of total)
No treatment Chronic PMA treatment
8Br-cAMP 0.46 þ 0.07 0.42 þ 0.05
dDAVP 0.57 þ 0.07 0.64 þ 0.10
CPA 0.39 þ 0.09 0.35 þ 0.06
8Br-cAMP+dDAVP 0.76 þ 0.07 0.77 þ 0.04
8Br-cAMP+CPA 0.68 þ 0.11 0.51 þ 0.09
dDAVP+CPA 0.56 þ 0.09 0.46 þ 0.07
Chronic phorbol ester treatment and PLD activity measure-
ments were performed as described in the legend of Fig. 2. Ad-
ditions were: 8Br-cAMP (0.1 mM; both sides), dDAVP (10
nM; basolateral side) and CPA (10 WM; apical side). For each
¢lter, the amount of [3H]PtdEth is expressed as the percentage
of total labelled lipid that was extracted. Of note, the values
for 8Br-cAMP, dDAVP and CPA alone are also shown in Figs.
2 and 3. The data presented show the mean þ S.E.M. of at least
three ¢lters. In none of the cases was the value obtained with
the combination signi¢cantly higher than that obtained with the
most active stimulant alone.
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contain substantial amounts of this PLD isoform.
RT-PCR on total RNA suggests that it concerns
the 1b splice variant of PLD1. In addition, the cells
gave a clear signal with speci¢c primers for PLD2. At
present, however, we do not know to what extent
this latter isoform is expressed at the protein level.
Thus far, Northern blot analysis has revealed the
presence of PLD1 as well as PLD2 transcripts in
human and rat kidney (listed in [30]).
Chronic phorbol ester treatment (120 h) did not
a¡ect PLD activation by the stimulatory hormones
CPA and dDAVP, while it markedly reduced PLD
activation by the inhibitory hormone ATP. These
¢ndings suggest that both the stimulatory and inhib-
itory pathways for Ca2 reabsorption lead to PLD
activation (for a schematic model, see Fig. 5). The
e¡ectiveness of chronic phorbol ester treatment was
demonstrated by abolition of PMA-induced PLD ac-
tivity. Chronic phorbol ester treatment has been used
in many cell systems to demonstrate the involvement
of phorbol ester-sensitive PKC isoforms in hormone-
stimulated PLD activity [26,31,32]. In other cell mod-
els, however, such treatment did not a¡ect hormone-
stimulated PLD activity [33^35]. In this context, rab-
bit cortical collecting system cells represent a unique
system in that chronic phorbol ester treatment inhib-
its PLD activation by one group of hormones (rep-
resented by ATP), while it does not a¡ect PLD acti-
vation by another group of hormones (represented
by dDAVP and CPA).
The present ¢nding that hormones that stimulate
Ca2 reabsorption increase PLD activity is in line
with the observation that PTH(1^84) stimulated the
transphosphatidylation reaction in immortalised
mouse distal convoluted tubule cells [18]. However,
our ¢nding that the inhibitory nucleotide ATP,
which in itself does not change basal Ca2 reabsorp-
tion [9], markedly increases PLD activity disfavours
the idea put forward by these authors that PLD may
represent the non-PtdIns-PLC pathway generating
6
Fig. 4. Chelerythrine does not a¡ect the ATP-induced increase
in PLD activity but markedly reduces the e¡ects of 8Br-cAMP,
dDAVP, CPA and PMA. PLD activity measurements were per-
formed as described in the legend of Fig. 2. Monolayers were
stimulated in the presence of chelerythrine (10 WM, both sides)
added 15 min prior to stimulation (closed bars). Additions
were: (A) PMA (0.1 WM; both sides) and 8Br-cAMP (0.1 mM;
both sides), and (B) ATP (0.1 mM; both sides), dDAVP (10
nM; basolateral side) and CPA (10 WM; apical side). For each
¢lter, the amount of [3H]PtdEth is expressed as the percentage
of total labelled lipid that was extracted. The data presented
show the mean þ S.E.M. of at least three ¢lters. pSigni¢cantly
lower than the value obtained with PMA (P6 0.05). *Signi¢-
cantly lower than the value without chronic phorbol ester treat-
ment (P6 0.05).
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the diacylglycerols for PKC-dependent Ca2 reab-
sorption.
In contrast to chronic phorbol ester treatment,
chelerythrine markedly inhibited PLD activation by
the stimulatory hormones CPA and dDAVP. This
¢nding is in agreement with the previous observation
that chelerythrine e¡ectively inhibits the stimulatory
e¡ect of these hormones on Ca2 reabsorption [4],
and stresses the idea that the same phorbol ester-
insensitive, chelerythrine-inhibitable pathway that
leads to increased Ca2 reabsorption also leads to
PLD activation (see also Fig. 5). Chelerythrine did
not a¡ect PLD activation by the inhibitory hormone
ATP. Nor did chelerythrine abolish the increase in
PLD activity evoked by PMA. These ¢ndings may
suggest that the phorbol ester-sensitive PKC path-
way used by ATP to activate PLD and inhibit hor-
mone-stimulated Ca2 reabsorption is less sensitive
to chelerythrine than the phorbol ester-insensitive
pathway used by the stimulatory hormones.
In addition to PMA, 8Br-cAMP markedly in-
creased PLD activity in these primary cultures.
This suggests the presence of a cAMP-dependent
pathway leading to PLD activation. Recently, the
existence of such a pathway has been reported in
FRTL-5 thyroid cells [36]. Chronic phorbol ester
treatment did not a¡ect 8Br-cAMP stimulation of
PLD activity, indicating that 8Br-cAMP, similar to
dDAVP and CPA but in contrast to ATP and PMA,
does not require the presence of phorbol ester-sensi-
tive PKC isoforms for activation of PLD. Similar to
dDAVP and CPA stimulation of PLD activity, 8Br-
cAMP stimulation of PLD activity was virtually
abolished by chelerythrine. Importantly, however,
the dDAVP-induced increase in PLD activity was
not reduced by the potent adenylyl cyclase inhibitor
DDA, indicating that dDAVP does not act via the
cAMP-dependent pathway. Similarly, the involve-
ment of the cAMP-dependent pathway in the mech-
anism of action of CPA is excluded by the fact that
CPA does not increase cAMP in these monolayers
[7]. These ¢ndings show that dDAVP and CPA do
not act through PKA to stimulate PLD activity.
When the inhibitory nucleotide ATP was added in
combination with either 8Br-cAMP, dDAVP or
CPA, the increase in PLD activity was higher than
that observed with each of the stimulants alone.
These observations are in agreement with the idea
that ATP and the stimulatory hormones activate
PLD via two distinct pathways. Conversely, none
of the combinations of the stimulatory hormones
gave an additive e¡ect. This latter observation sug-
gests that the pathway used by the stimulatory hor-
mones is already maximally activated by each of the
hormones. The observation that addition of 8Br-
cAMP did not lead to a further increase of PMA-
stimulated PLD activity then suggests that the phor-
bol ester-sensitive PKC pathway, in contrast to the
phorbol ester-insensitive pathway, can fully activate
PLD.
It is unknown at which of the steps involved in
transepithelial Ca2 transport, i.e. apical Ca2 in£ux,
cytosolic di¡usion of Ca2 bound to calbindin or
basolateral Ca2 extrusion, the regulatory hormones
act. However, voltage-clamp studies with Xenopus
laevis oocytes heterologously expressing the recently
cloned ECaC provide evidence for a strong inhibition
of Ca2 in£ux by intracellular Ca2, suggesting that
ECaC is a major site for regulation of Ca2 reab-
sorption [37]. Moreover, elucidation of the primary
structure of ECaC revealed the presence of seven
potential PKC phosphorylation sites [3], and future
Fig. 5. Schematic model of the hormonal regulation of PLD ac-
tivity in rabbit CNT and CCD cells. For explanation see text.
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studies will decide whether or not these sites are in-
volved in the hormonal regulation of Ca2 reabsorp-
tion.
In conclusion, the present observation that both
hormones that stimulate and those that inhibit
Ca2 reabsorption readily increase PLD activity sug-
gests that PLD activation does not play a role in the
mechanism by which these hormones exert their reg-
ulatory action. The physiological relevance of PLD
activation in CNT and CCD cells is at present un-
clear and awaits further investigation.
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